It is very uncertain whether bleomycin changes clinical response ‐ partial response compared with ABV (very low certainty).
It is very uncertain whether bleomycin changes clinical response ‐ stable disease compared with ABV (very low certainty).
It is very uncertain whether bleomycin changes clinical response ‐ progression compared with ABV (very low certainty).
It is very uncertain whether bleomycin changes adverse events compared with ABV (very low certainty).
Liposomal doxorubicin showed no clear difference in mortality compared with conservative management (moderate certainty).
HAART + ABV showed no clear difference in clinical response ‐ complete response compared with HAART alone (moderate certainty).
HAART + ABV probably leads to higher clinical response ‐ partial response compared with HAART alone (moderate certainty).
HAART + ABV probably leads to lower clinical response ‐ stable disease compared with HAART alone (moderate certainty).
HAART + ABV probably leads to higher clinical response ‐ overall response (complete and partial) compared with HAART alone (moderate certainty).
HAART + ABV showed no clear difference in adverse events compared with HAART alone (moderate certainty).
HAART + pegylated liposomal doxorubicin showed no clear difference in clinical response compared with HAART alone (moderate certainty).
HAART + liposomal anthracycline showed no clear difference in mortality compared with HAART alone (moderate certainty).
Structural and community‐level interventions for increasing condom use showed no clear difference in HIV incidence (person/years) compared with standard care (moderate certainty).
Structural and community‐level interventions for increasing condom use showed no clear difference in HIV prevalence compared with standard care (low certainty).
Structural and community‐level interventions for increasing condom use showed no clear difference in herpes Simplex Virus 2 (HSV‐2) incidence (person/years) compared with standard care (moderate certainty).
Structural and community‐level interventions for increasing condom use showed no clear difference in HSV‐2 prevalence compared with standard care (moderate certainty).
Structural and community‐level interventions for increasing condom use showed no clear difference in two or more sexual partners in last year compared with standard care (moderate certainty).
Structural and community‐level interventions for increasing condom use probably leads to higher use of condom during last sexual intercourse compared with standard care (moderate certainty).
Structural and community‐level interventions for increasing condom use probably leads to higher knowledge: condom can prevent STIs compared with standard care (moderate certainty).